SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
Dimitrios PatouliasTheodoros MichailidisPublished in: Journal of clinical and translational hepatology (2022)